Raymond James Financial
SLN

Raymond James Financial’s Silence Therapeutics SLN Stock Holding History

Raymond James Financial’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$132K Hold
25,000
– – ﹤0.01% 4981
2025
Q4 		$152K Buy
+25,000
New +$160K ﹤0.01% 4849

Other funds holding SLN

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Raymond James Financial's SLN Position: Q1 2026 in Review

Raymond James Financial held its Silence Therapeutics (SLN) position steady in Q1 2026 at 25,000 shares worth $132K. The position accounts for ﹤0.01% of the portfolio, ranked #4981.

Raymond James Financial first reported a position in SLN in Q4 2025 and has held it in 2 quarters since. The position peaked at $152K in Q4 2025. 56 funds tracked by Wall St. Rank hold SLN as of Q1 2026.

  • Raymond James Financial held 25,000 shares of Silence Therapeutics worth $132K as of Q1 2026.
  • Raymond James Financial left its Silence Therapeutics share count unchanged in Q1 2026.
  • Silence Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #4981 holding.
  • Raymond James Financial first reported a position in Silence Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Raymond James Financial's Silence Therapeutics position peaked at $152K in Q4 2025.
  • 56 funds tracked by Wall St. Rank held Silence Therapeutics as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.